Business
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)
Patient received KYV-101, a fully human anti-CD19 CAR T-cell product candidate, as part of a named-patient treatment option after failure to respond to
About this update from Kyverna Therapeutics, Inc.
[{"type":"text","content":"Patient received KYV-101, a fully human anti-CD19 CAR T-cell product candidate, as part of a named-patient treatment option after failure to respond to conventional therapies\nSignificant improvement in walking distance and 40% reduction in GABAergic medications were among the reported results\nWell-tolerated treatment with low-grade CRS and no ICANS supports continued exploration of KYV-101 in neuroimmunological disease\nEMERYVILLE, Calif., June 17, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today the publication in Proceedings of the National Academy of Sciences (PNAS)1 of a report describing the first use of KYV-101, a fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, in a 69-year-old patient suffering from treatment-refractory stiff-person syndrome (SPS) as part of a named-patient use in Germany for critically ill individuals who fail conventional therapies. \n\n \n \n \n \n \n \n\n \n\"It is extremely encouraging to see this patient improving the self-reported, uninterrupted walking distance from less than 50 meters to several kilometers within three months after treatment,\" said Simon Faissner, M.D., professor for translational neuroimmunology at the Department of Neurology, Ruhr University Bochum, St. Josef Hospital, in Germany, and lead co-author. \"These dramatic improvements – if confirmed by further studies – may eventually provide renewed hope for a much-needed paradigm shift in the treatment of debilitating autoimmune diseases.\"\n\"It is remarkable to observe the transformational effects in a patient deemed refractory to available standard treatments. With the disease progressing over several years despite the best medical treatment, I recommended the CAR T-cell therapy approach,\" said Ralf Gold, M.D., professor of Medicine, chair of Neurology at Ruhr University Bochum, St. Josef Hospital, in Germany, and senior co-author. \"The absence of observed neurotoxicity and the measured impact on the pathogenic anti-GAD65 autoantibodies pave the way for additional studies to confirm the initial, promising findings.\" \n\"On the heels of recent case reports of the use of KYV-101 in multiple sclerosis and myasthenia gravis,...